• FOXM1–ERα ceRNA Network in Female Lung Adenocarcinoma: Bioma

  2026-05-06

  This study systematically identifies and validates a ceRNA network involving FOXM1 and estrogen receptor alpha (ERα) in female lung adenocarcinoma (LUAD). By integrating multi-omics data and experimental analysis, the authors reveal the prognostic significance and potential immunotherapeutic implications of this axis, providing a foundation for biomarker-driven research in hormone-responsive lung cancer.

• Translating α2-Adrenergic Agonist B3465 into Immune Oncology

  2026-05-05

  Explore the unique translational advantages of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine as an α2-adrenergic receptor agonist for advanced immune rejection modulation. This article delivers actionable assay insights and dissects novel findings on immune-driven osteosarcoma recurrence prevention.

• Selective CUX2 Neuron Loss in Neuroinflammation via DNA Dama

  2026-05-05

  This study reveals that DNA damage accumulation drives selective loss of CUX2-expressing cortical neurons during neuroinflammation, particularly in multiple sclerosis (MS). The findings clarify cell-type-specific vulnerability mechanisms and highlight the role of impaired DNA repair in neurodegenerative progression.

• Erlotinib (NSC 718781): Precision EGFR Inhibition for Cancer

  2026-05-04

  Erlotinib (NSC 718781) stands out as a highly potent, selective EGFR tyrosine kinase inhibitor, enabling reproducible dissection of EGFR signaling and resistance mechanisms in cancer models. This article translates advanced findings into optimized protocols, troubleshooting, and comparative strategies for researchers seeking rigorous, publishable results.

• Nitrocefin: Chromogenic Cephalosporin Substrate for β-Lactam

  2026-05-04

  Nitrocefin’s rapid colorimetric shift makes it the gold standard for detecting β-lactamase activity and antibiotic resistance in research settings. This article delivers hands-on workflows, troubleshooting tips, and an in-depth look at key innovations from recent studies, empowering users to optimize every β-lactamase assay.

• Scenario-Driven Best Practices with Angiotensin 1/2 (5-7) in

  2026-05-03

  This article delivers laboratory-tested strategies for deploying Angiotensin 1/2 (5-7) (SKU A1049) in cell viability and signaling assays. It addresses reproducibility, solubility, and protocol optimization using evidence-backed Q&A scenarios, helping researchers achieve reliable outcomes in renin-angiotensin system and viral pathogenesis studies. APExBIO's formulation is highlighted for its analytical purity and workflow compatibility.

• HyperScript RT SuperMix for qPCR: Precision cDNA Synthesis f

  2026-05-02

  HyperScript RT SuperMix for qPCR empowers researchers to decode gene expression accurately, even from low-concentration or structurally challenging RNA. Its advanced enzyme design and optimized primer blend streamline two-step qRT-PCR, making it a trusted choice for biomarker discovery, translational research, and studies tackling complex transcriptomes.

• Pepstatin A: Applied Workflows in Aspartic Protease Inhibiti

  2026-05-02

  Pepstatin A empowers researchers with precise aspartic protease inhibition, unlocking new frontiers in viral protein processing and osteoclast differentiation. This article bridges current evidence with advanced workflows, troubleshooting, and protocol optimization for robust, reproducible results.

• Resiniferatoxin (RTX): Reliable TRPV1 Agonist for Pain Assay

  2026-05-01

  This article presents practical laboratory scenarios highlighting the use of Resiniferatoxin (RTX, SKU BA7012) as a highly selective, ultra-potent TRPV1 agonist for pain, cytotoxicity, and inflammation studies. It synthesizes evidence-based guidelines and workflow optimizations to help researchers achieve reproducible, sensitive data using RTX from APExBIO.

• Molecular Mechanisms of Paroxetine: Beyond SSRI Activity

  2026-04-30

  The reference review systematically maps the molecular mechanisms of Paroxetine, a selective serotonin reuptake inhibitor, highlighting its diverse pharmacological targets beyond SERT inhibition. By dissecting interactions with cytochrome P450 enzymes, GRK2, and receptor tyrosine kinases, the review advances understanding of Paroxetine Mesylate’s pleiotropic effects, informing both psychiatric and translational oncology research.

• α-KG Restores Mitochondrial Function to Counter HPDLSC Senes

  2026-04-30

  This study demonstrates that α-ketoglutarate (α-KG) alleviates mitochondrial dysfunction and reduces senescence in human periodontal ligament stem cells (HPDLSCs) under inflammatory stress by activating the LKB1-AMPK pathway. The findings provide mechanistic insight into how metabolic modulation may promote periodontal tissue regeneration, with implications for developing targeted therapies against inflammation-induced cellular aging.

• Novobiocin Sodium: Applied Workflows for DNA Damage Research

  2026-04-29

  Novobiocin Sodium, a potent aminocoumarin antibiotic, offers researchers precision control over bacterial DNA replication and membrane synthesis—enabling advanced cell cycle, apoptosis, and antibiotic resistance studies. Drawing on recent evidence, this guide spotlights actionable protocols, troubleshooting strategies, and the unique innovation of vacuole formation inhibition in Enterococcus faecalis protoplasts.

• ECL Western Blotting Substrate: Technical Workflow & QC Guid

  2026-04-29

  ECL Western Blotting Substrate (SKU K2187) provides a sensitive, nonradioactive solution for detecting HRP-labeled proteins by chemiluminescence in Western blot assays. This product is recommended for molecular biology, cancer biology, and signal transduction pathway research, but should not be used in fluorescent or radioisotopic workflows.

• Quinolone–Coumarin Hybrids Show Anti-Toxoplasma Activity In

  2026-04-28

  This study systematically evaluates quinolone–coumarin hybrids, derived from fluoroquinolones and novobiocin, for their anti-parasitic efficacy against Toxoplasma gondii in vitro. The results highlight several hybrids with improved selectivity and potency compared to standard therapies, suggesting new avenues for anti-Toxoplasma drug development.

• Pomalidomide (CC-4047): Resolving Core Challenges in Myeloma

  2026-04-28

  This article addresses persistent laboratory challenges in multiple myeloma and hematological malignancy research, showing how 'Pomalidomide (CC-4047)' (SKU A4212) delivers reliable, evidence-backed solutions. Through scenario-driven Q&A and direct application insights, we demonstrate the value of APExBIO's formulation for reproducibility and workflow optimization.

449 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page